KEAP1 and Parkinson disease: Although previous studies have shown that ICS might achieve antioxidant effects by activating Nrf2-related protein expression and decreasing ROS levels in several diseases [50–52], we collected evidence for the first time that ICS could combat METH-induced neurotoxicity and PD-like symptoms through mediating the classic antioxidant Keap1-Nrf2 pathway and oxidative stress.